MetaCap

Ensysce Biosciences (ENSC) vs Alaunos Therapeutics (TCRT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ensysce Biosciences is the larger company by market cap ($7.0 million vs $7.0 million), about 1.0 times the size. Ensysce Biosciences converts more of its revenue into profit, with a net margin of -200.8% versus -83520.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENSC-16.16%TCRT+98.07%
+288%+125%-38%
Oct 7, 20261 yearNov 20, 2026
ENSC-31.69%TCRT+111.25%
+248%+99%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENSC versus TCRT key metrics
MetricENSCTCRT
Share price$0.36$1.66
Market cap$7.00M$6.99M
1-day change-0.17%+3.75%
EPS (TTM)$-7.51$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.07M$5.00K
Revenue growth (YoY)-2.75%-50.00%
Net income (latest FY)$-10.18M$-4.18M
Operating margin-202.12%-84500.00%
Net margin-200.85%-83520.00%
52-week high$1.85$4.50
52-week low$0.23$0.72
Distance from 52-week high-80.54%-63.11%
Analyst consensusnone—
Avg. price target upside+2191.67%—
Average volume493.43K7.56M
Shares outstanding19.46M4.21M
Employees81
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Ensysce Biosciences is more profitable, keeping -200.8 cents of every revenue dollar as net income versus -83520.0 cents for Alaunos Therapeutics.
  • Ensysce Biosciences grew revenue faster in its latest fiscal year (-2.75% vs -50.00%).

About Ensysce Biosciences

ENSC stock →

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Alaunos Therapeutics

TCRT stock →

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

ENSC vs TCRT FAQ

Which is bigger, Ensysce Biosciences or Alaunos Therapeutics?

Ensysce Biosciences (ENSC) is larger, with a market capitalization of $7.00M compared with $6.99M for Alaunos Therapeutics (TCRT).

Are Ensysce Biosciences and Alaunos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons